BACKGROUND: Both medial temporal cortical dysfunction and perturbed glutamatergic neurotransmission are regarded as fundamental pathophysiological features of psychosis. However, although animal models of psychosis suggest that these two abnormalities are interrelated, their relationship in humans has yet to be investigated. METHODS: We used a combination of functional magnetic resonance imaging and magnetic resonance spectroscopy to investigate the relationship between medial temporal activation during an episodic memory task and local glutamate levels in 22 individuals with an at-risk mental state for psychosis and 14 healthy volunteers. RESULTS: We observed a significant between-group difference in the coupling of medial temporal activation with local glutamate levels. In control subjects, medial temporal activation during episodic encoding was positively associated with medial temporal glutamate. However, in the clinical population, medial temporal activation was reduced, and the relationship with glutamate was absent. CONCLUSIONS: In individuals at high risk of psychosis, medial temporal dysfunction seemed related to a loss of the normal relationship with local glutamate levels. This study provides the first evidence that links medial temporal dysfunction with the central glutamate system in humans and is consistent with evidence that drugs that modulate glutamatergic transmission might be useful in the treatment of psychosis.
BACKGROUND: Both medial temporal cortical dysfunction and perturbed glutamatergic neurotransmission are regarded as fundamental pathophysiological features of psychosis. However, although animal models of psychosis suggest that these two abnormalities are interrelated, their relationship in humans has yet to be investigated. METHODS: We used a combination of functional magnetic resonance imaging and magnetic resonance spectroscopy to investigate the relationship between medial temporal activation during an episodic memory task and local glutamate levels in 22 individuals with an at-risk mental state for psychosis and 14 healthy volunteers. RESULTS: We observed a significant between-group difference in the coupling of medial temporal activation with local glutamate levels. In control subjects, medial temporal activation during episodic encoding was positively associated with medial temporal glutamate. However, in the clinical population, medial temporal activation was reduced, and the relationship with glutamate was absent. CONCLUSIONS: In individuals at high risk of psychosis, medial temporal dysfunction seemed related to a loss of the normal relationship with local glutamate levels. This study provides the first evidence that links medial temporal dysfunction with the central glutamate system in humans and is consistent with evidence that drugs that modulate glutamatergic transmission might be useful in the treatment of psychosis.
Authors: Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero Journal: Eur Neuropsychopharmacol Date: 2014-08-01 Impact factor: 4.600
Authors: C Christoph Schultz; Paolo Fusar-Poli; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Oliver Gruber; Heinrich Sauer; Ralf G M Schlösser Journal: Eur Arch Psychiatry Clin Neurosci Date: 2012-09-02 Impact factor: 5.270
Authors: Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis Journal: Schizophr Res Date: 2014-01-11 Impact factor: 4.939
Authors: Shima Shakory; Jeremy J Watts; Sina Hafizi; Tania Da Silva; Saad Khan; Michael Kiang; R Michael Bagby; Sofia Chavez; Romina Mizrahi Journal: Neuropsychopharmacology Date: 2018-07-28 Impact factor: 7.853
Authors: A D Stan; S Ghose; C Zhao; K Hulsey; P Mihalakos; M Yanagi; S U Morris; J J Bartko; C Choi; C A Tamminga Journal: Mol Psychiatry Date: 2014-06-10 Impact factor: 15.992
Authors: E M P Poels; L S Kegeles; J T Kantrowitz; M Slifstein; D C Javitt; J A Lieberman; A Abi-Dargham; R R Girgis Journal: Mol Psychiatry Date: 2013-10-29 Impact factor: 15.992